BR9807980A - Use of a compound and compound to treat a mammal with cognitive impairment - Google Patents

Use of a compound and compound to treat a mammal with cognitive impairment

Info

Publication number
BR9807980A
BR9807980A BR9807980-8A BR9807980A BR9807980A BR 9807980 A BR9807980 A BR 9807980A BR 9807980 A BR9807980 A BR 9807980A BR 9807980 A BR9807980 A BR 9807980A
Authority
BR
Brazil
Prior art keywords
compound
mammal
breflato
treat
cognitive impairment
Prior art date
Application number
BR9807980-8A
Other languages
Portuguese (pt)
Inventor
Richard L Gabriel
Original Assignee
Allelix Pharm Eco L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Pharm Eco L P filed Critical Allelix Pharm Eco L P
Publication of BR9807980A publication Critical patent/BR9807980A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

"USO DE UM COMPOSTO E COMPOSTO PARA TRATAR DE MAMìFERO COM DISFUNçãO COGNITIVA". Descritos estão métodos para tratar um mamífero sofrendo de disfunção cognitiva. O método compreende administrar uma quantidade terapeuticamente efetiva de Breflato ou de um derivado de Breflato, como descrito aqui. Também descritos estão métodos para melhorar funções cognitivas em um mamífero. O método compreende administrar uma quantidade intensificadora cognitiva efetiva de Breflato ou de um derivado de Breflato, como descrito aqui."USE OF A COMPOUND AND COMPOUND TO TREAT MAMMALIAN WITH COGNITIVE DYSFUNCTION". Described are methods for treating a mammal suffering from cognitive impairment. The method comprises administering a therapeutically effective amount of Breflato or a Breflato derivative, as described herein. Also described are methods for improving cognitive functions in a mammal. The method comprises administering an effective cognitive enhancing amount of Breflato or a Breflato derivative, as described here.

BR9807980-8A 1997-02-05 1998-02-04 Use of a compound and compound to treat a mammal with cognitive impairment BR9807980A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3688997P 1997-02-05 1997-02-05
PCT/US1998/002009 WO1998033498A1 (en) 1997-02-05 1998-02-04 Drugs for memory enhancement

Publications (1)

Publication Number Publication Date
BR9807980A true BR9807980A (en) 2000-03-28

Family

ID=21891226

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807980-8A BR9807980A (en) 1997-02-05 1998-02-04 Use of a compound and compound to treat a mammal with cognitive impairment

Country Status (6)

Country Link
EP (1) EP0969830A1 (en)
JP (1) JP2001512422A (en)
AU (1) AU6141798A (en)
BR (1) BR9807980A (en)
CA (1) CA2279947A1 (en)
WO (1) WO1998033498A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160649A0 (en) * 2001-08-31 2004-07-25 Corcept Therapeutics Inc Methods for inhibiting cognitive deterioration in adults with down syndrome
WO2010068173A1 (en) 2008-12-12 2010-06-17 Daniel Klamer L-lysine for improving normal cognitive functions
CN112851622B (en) * 2019-11-28 2023-01-10 中国海洋大学 Macrolide brefeldin A ester derivative and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5696154A (en) * 1994-06-29 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Brefeldin A derivatives and their utility in the treatment of cancer
ATE190056T1 (en) * 1994-09-20 2000-03-15 Univ California BREFELDIN A AND ANALOGUE FOR IMPROVEMENT OF SYNAPTIC TRANSMISSIONS
US5618837A (en) * 1995-06-07 1997-04-08 Zymogenetics, Inc. PDGF antagonists III

Also Published As

Publication number Publication date
AU6141798A (en) 1998-08-25
WO1998033498A1 (en) 1998-08-06
EP0969830A1 (en) 2000-01-12
CA2279947A1 (en) 1998-08-06
JP2001512422A (en) 2001-08-21

Similar Documents

Publication Publication Date Title
BR9710689A (en) Process for treating acute diarrhea and for providing therapy to a mammal having diarrhea and therapeutic preparation for reducing diarrhea symptoms
BR9811012A (en) "use of a compound".
ATE249421T1 (en) INHIBITORS OF ALPHA4-BETA1-MEDIATED CELL ADHESION
EA199800667A1 (en) NEW PHENANTRIDINES
EA199900324A1 (en) COMBINED THERAPY FOR THE TREATMENT OF PSYCHOSIS
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
ES2163034T3 (en) MICELLARY COMPOSITIONS OF POLYETER BLOCK COPOLYMERS, FOR THE OBJECTIVATION OF BIOLOGICAL AGENTS AS DIANA.
FI971420A0 (en) A method for treating diabetes mellitus using KGF
EA199900421A1 (en) PETROPHYDRIDINE AS BRONCHIAL THERAPEUTIC TOOLS
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
BR9808221A (en) Tumor treatment method.
AU1711197A (en) Method for treating sexual dysfunctions
DE69625682D1 (en) METHOD FOR TREATING IGNITIONS AND COMPOSITIONS THEREFOR
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
EA199700241A1 (en) NEW, DETERMINED BY COMPOSITION OF A MIXTURE OF ENZYMES FOR ISOLATION OF CELLS AND TREATMENT OF THE RAS
BR9807980A (en) Use of a compound and compound to treat a mammal with cognitive impairment
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
BR9708525A (en) Method of treating heart failure with endothelin antagonists
ATE316136T1 (en) RENAL POLYCYSTosis GENE
EA199800819A1 (en) METHOD OF TREATMENT OF BIPOLAR DISORDER
IL139303A0 (en) Treatment of arthritis and other similar conditions
EA199900543A1 (en) Leukotriene antagonists for the treatment of epithelial flat-cell carcinoma of the oral cavity
ATE306278T1 (en) TREATING BONE DISEASES WITH ADRENOMEDULLIN
EA199800822A1 (en) METHOD FOR TREATING EXCESSIVE AGGRESSION
ATE260111T1 (en) AGENTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired